Agile Therapeutics Non-GAAP EPS of -$0.63, revenue of $5.7M

Stock Information for Agile Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Agile Therapeutics Inc.

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENV, SPR, UMBF, AGRX on Behalf of Shareholders
Kuehn Law Encourages AGRX, SPR, ENV, and UMBF Investors to Contact Law Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, DM, AGRX on Behalf of Shareholders
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRX
Kuehn Law Encourages AGRX, SPR, HCP, and ALLG Investors to Contact Law Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INFN, SPR, AGRX, GRDI on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SHCR, AGRX on Behalf of Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.